Neuronetics, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a STIM research report →
Companywww.neurostar.com
Neuronetics, Inc. , a commercial stage medical technology company, designs, develops, and markets products for patients with neurohealth disorders in the United States and internationally. The company offers NeuroStar Advanced Therapy System, a non-invasive and non-systemic office-based treatment to treat adult patients with major depressive disorder.
- CEO
- Daniel L. Reuvers
- IPO
- 2018
- Employees
- 716
- HQ
- Malvern, PA, US
Price Chart
Valuation
- Market Cap
- $82.81M
- P/E
- -2.23
- P/S
- 0.55
- P/B
- 6.24
- EV/EBITDA
- -3.58
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 47.96%
- Op Margin
- -19.40%
- Net Margin
- -24.48%
- ROE
- -164.68%
- ROIC
- -28.68%
Growth & Income
- Revenue
- $149.16M · 99.17%
- Net Income
- $-38,998,000 · 10.78%
- EPS
- $-0.59 · 57.25%
- Op Income
- $-31,436,000
- FCF YoY
- 34.77%
Performance & Tape
- 52W High
- $4.85
- 52W Low
- $0.80
- 50D MA
- $1.50
- 200D MA
- $2.11
- Beta
- 1.13
- Avg Volume
- 2.20M
Get TickerSpark's AI analysis on STIM
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| May 19, 26 | Chernett Jorey | buy | 100,000 |
| May 5, 26 | BROWN FRANCIS X III | other | 0 |
| May 12, 26 | Chernett Jorey | buy | 475,000 |
| Apr 21, 26 | Chernett Jorey | buy | 100,000 |
| Apr 20, 26 | Chernett Jorey | buy | 100,000 |
| Jul 10, 25 | Madryn Asset Management, LP | other | 337,312 |
| Jul 10, 25 | Madryn Asset Management, LP | other | 337,312 |
| Mar 30, 26 | Chernett Jorey | buy | 385,442 |
| Mar 27, 26 | Chernett Jorey | buy | 500,000 |
| Mar 26, 26 | Chernett Jorey | buy | 25,000 |
Our STIM Coverage
We haven't published any research on STIM yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate STIM Report →